Erythropoietin Resistance in Anemia of Chronic Kidney Disease
This study has been completed.
Information provided by (Responsible Party):
First received: September 6, 2007
Last updated: April 9, 2013
Last verified: November 2008
Our goal of this pilot project is to identify inflammatory biomarkers that correlate with epo-resistance among CKD patients.
|Official Title:||Novel Biomarkers of Erythropoietin Resistant Anemia Among Patients With Chronic Kidney Disease|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Duke University:
|Study Start Date:||August 2007|
|Study Completion Date:||June 2008|
|Primary Completion Date:||June 2008 (Final data collection date for primary outcome measure)|
Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are requiring <100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00526747
|United States, North Carolina|
|Duke University Medical Center Anemia Clinic|
|Durham, North Carolina, United States, 27705|
|Durham Nephrology Anemia Clinic|
|Durham, North Carolina, United States, 27704|
Sponsors and Collaborators
|Principal Investigator:||Jula Inrig, MD, MHS||Duke University|
|Principal Investigator:||Lynda Szczech, MD||Duke University|
|Principal Investigator:||Suzanne K Bryskin, MD||Duke University|